



AgiOS to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC

October 26, 2015

Investor Lunch and Webcast on Sunday, November 8, 2015

CAMBRIDGE, Mass., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the first results from the Phase 1 study of AG-120 in patients with IDH1-mutant positive advanced solid tumors will be presented in an oral presentation and featured in the press program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place November 5-9, 2015, in Boston.

"We look forward to sharing the first clinical data for AG-120 in patients with advanced solid tumors as we continue to understand the potential of this investigational medicine," said Chris Bowden M.D., chief medical officer at Agios. "This is an important step toward our long-term vision of making a difference for people with a broad range of hematologic and solid tumor cancers that harbor IDH mutations."

Title: The First Reported Results of AG-120, a First-in-class, Potent Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of Patients with Advanced IDH1-Mutant Solid Tumors, Including Gliomas

Plenary Session Date & Time: Sunday, November 8, 2015, at 8:00 a.m. ET

Session: Advances in Targeted Therapy

Press Program Date & Time: Sunday, November 8, 2015, at 10:30 a.m. ET

Presenter: Howard A. Burris, III, M.D., Sarah Cannon Cancer Center, Nashville, Tennessee

Location: Hynes Convention Center

Investor Lunch and Webcast Information

AgiOS will host an investor lunch on Sunday, November 8, 2015 in Boston to review data presented at the conference, additional event details to come. The event will be webcast live and can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for approximately 30 days following the presentation.

About Agios

AgiOS Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and rare genetic disorders of metabolism through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in cancer metabolism and rare genetic disorders of metabolism in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging the company's knowledge of metabolism, biology and genomics. For more information, please visit Agios' website at www.agios.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of Agios' product candidates targeting IDH mutations, including AG-120; its plans for the clinical development of AG-120; its plans regarding future data presentations; and the benefit of its strategic plans and focus. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "potential," "hope," "could," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios' product candidates will successfully continue. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to maintain key collaborations, such as its agreement with Celgene; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, and other filings that Agios may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Renee Leck, Senior Manager,
Investor Relations and Public Relations
Renee.Leck@agios.com
617-649-8299

[Agios Pharmaceuticals logo](#)

Agios Pharmaceuticals